Rifamycin SV-MMX® as the recommended self-treatment for moderate to severe travellers’ diarrhoea: reply

por Steffen, Robert, DuPont, Herbert L
Publicado 2019

The Importance of a Healthy Microbiome in Pregnancy and Infancy and Microbiota Treatment to Reverse Dysbiosis for Improved Health

por DuPont, Herbert L., Salge, Madeleine Mary Hines
Publicado 2023

Accessory Gene Regulator-1 Locus Is Essential for Virulence and Pathogenesis of Clostridium difficile

por Darkoh, Charles, Odo, Chioma, DuPont, Herbert L.
Publicado 2016

Erratum for Darkoh et al., “Accessory Gene Regulator-1 Locus Is Essential for Virulence and Pathogenesis of Clostridium difficile”

por Darkoh, Charles, Odo, Chioma, DuPont, Herbert L.
Publicado 2017

The role of rifaximin in the treatment and chemoprophylaxis of travelers’ diarrhea

por Koo, Hoonmo L, DuPont, Herbert L, Huang, David B
Publicado 2009

Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review

por Chey, William D., Shah, Eric D., DuPont, Herbert L.
Publicado 2020

Clostridium difficile Modulates the Gut Microbiota by Inducing the Production of Indole, an Interkingdom Signaling and Antimicrobial Molecule

por Darkoh, Charles, Plants-Paris, Kimberly, Bishoff, Dayna, DuPont, Herbert L.
Publicado 2019

Development of a new travellers’ diarrhoea clinical severity classification and its utility in confirming rifamycin-SV efficacy

por DuPont, Herbert L, Almenoff, June S, Jamindar, Mansi S, Bortey, Enoch, Steffen, Robert
Publicado 2023

Bile Salt Inhibition of Host Cell Damage by Clostridium Difficile Toxins

por Darkoh, Charles, Brown, Eric L., Kaplan, Heidi B., DuPont, Herbert L.
Publicado 2013

Rifaximin Therapy of Irritable Bowel Syndrome

por Koo, Hoonmo L., Sabounchi, Saman, Huang, David B., DuPont, Herbert L.
Publicado 2012

Toxin Synthesis by Clostridium difficile Is Regulated through Quorum Signaling

por Darkoh, Charles, DuPont, Herbert L., Norris, Steven J., Kaplan, Heidi B.
Publicado 2015

Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin

por DuPont, Herbert L., Wolf, Ray A., Israel, Robert J., Pimentel, Mark
Publicado 2016

Chemotactic Chemokines Are Important in the Pathogenesis of Irritable Bowel Syndrome

por Darkoh, Charles, Comer, Latoya, Zewdie, Getie, Harold, Stephen, Snyder, Ned, DuPont, Herbert L.
Publicado 2014

Rifaximin-Mediated Changes to the Epithelial Cell Proteome: 2-D Gel Analysis

por Schrodt, Caroline, McHugh, Erin E., Gawinowicz, Mary Ann, DuPont, Herbert L., Brown, Eric L.
Publicado 2013

1694. Successful Gut Decolonization of Extended-Spectrum β-lactamase Producing Klebsiella pneumoniae Using Oral Lyophilized Fecal Microbiota Transplant (FMT) in a Woman with Recurr...

por Bier, Naomi, Hanson, Blake, Jiang, Zhi-Dong, DuPont, Herbert, Arias, Cesar A, Miller, William R
Publicado 2020

Intestinal IgA-Coated Bacteria in Healthy- and Altered-Microbiomes (Dysbiosis) and Predictive Value in Successful Fecal Microbiota Transplantation

por DuPont, Herbert L., Jiang, Zhi-Dong, Alexander, Ashley S., DuPont, Andrew W., Brown, Eric L.
Publicado 2022

Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)

por Golan, Yoav, DuPont, Herbert L, Aldomiro, Fernando, Jensen, Erin H, Hanson, Mary E, Dorr, Mary Beth
Publicado 2017

Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials

por Golan, Yoav, DuPont, Herbert L, Aldomiro, Fernando, Jensen, Erin H, Hanson, Mary E, Dorr, Mary Beth
Publicado 2020

Corrigendum to: Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials

por Golan, Yoav, DuPont, Herbert L, Aldomiro, Fernando, Jensen, Erin H, Hanson, Mary E, Dorr, Mary Beth
Publicado 2021